Circulating Relaxin-1 Level Is a Surrogate Marker of Myocardial Fibrosis in HFrEF

Introduction: Relaxin-1 (RLN1) has emerged as a possible therapeutic target in myocardial fibrosis due to its anti-fibrotic effects. Previous randomized clinical trials investigated therapeutic role of exogenous relaxin in patients with acute-on-chronic heart failure (HF) and failed to meet clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Simon, Judit, Nemeth, Endre, Nemes, Annamaria, Husveth-Toth, Maria, Radovits, Tamas, Foldes, Gabor, Kiss, Loretta, Bagyura, Zsolt, Skopal, Judit, Merkely, Bela, Gara, Edit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Physiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558211/
https://www.ncbi.nlm.nih.gov/pubmed/31231242
http://dx.doi.org/10.3389/fphys.2019.00690

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558211/
https://www.ncbi.nlm.nih.gov/pubmed/31231242
http://dx.doi.org/10.3389/fphys.2019.00690

Ejemplares similares